Company: ZVRA
Filing Date: 2025-03-31
Form Type: DEFA14A
Source: 0001193125-25-068853
Chunk: 0

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☒ | Soliciting Material under §240.14a-12 |

Zevra Therapeutics, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required |

| ☐ | Fee paid previously with preliminary materials |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11                                                           |

Zevra Therapeutics: All Employee Email

All,

Earlier today, we filed our preliminary proxy statement, which relates to matters to be voted upon by stockholders at our 2025 annual meeting of stockholders,
including the re-election of Tamara Favorito and Wendy Dixon, Ph.D. to our Board. This document disclosed that one of our stockholders, Daniel J. Mangless, has proposed alternative director nominees: Travis C.
Mickle, Ph.D. and Arthur C. Regan.

Public companies like Zevra are subject to high levels of scrutiny at times, which can lead to situations like this.
Please know that the Board and management team have engaged with Mr. Mangless and are well advised in managing this situation.

So, what does this
mean for you?

While the filing of our preliminary proxy statement makes Mr. Mangless’s nominations public and therefore may attract additional
public attention, it is business as usual for all of us. We need to focus on our day-to-day responsibilities as we remain committed to making life-changing therapeutics
available to patients suffering from rare disease with high unmet needs.

It is also important that we speak with one voice and